A phase 1 open-label pilot study of low-dose interleukine-2 immunotherapy in patients with Alzheimer's disease.

ABSTRACT:

Trial registration

ClinicalTrials.gov Identifier: NCT05821153, Registered April 20 2023, Retrospectively registered, https://classic.

Clinicaltrials

gov/ct2/show/NCT05821153.

SUBMITTER: Faridar A 

PROVIDER: S-EPMC10652426 | biostudies-literature | 2023 Nov

REPOSITORIES: biostudies-literature